Respiratory Tract Neoplasms clinical trials
The registry lists 60 studies for Respiratory Tract Neoplasms across more than 10 countries. 16 are recruiting or about to start. 2 of them are mainly about Respiratory Tract Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 13 narrower conditions too, such as Carcinoma, Non-Small-Cell Lung: 12,934 studies, 3,314 open.
Get an email when these change. Save the Respiratory Tract Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Revolution Medicines, Inc. (6) · AstraZeneca (6) · Fundación GECP (6) · Blueprint Medicines Corporation (4) · Eli Lilly and Company (4) · Syndax Pharmaceuticals (3) · Hoffmann-La Roche (3) · Daiichi Sankyo Co., Ltd. (2)
What is being tested here
Drugs under test in Respiratory Tract Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Elironrasib | 1 | 0 | 2 |
| Zopapogene imadenovec | 1 | 0 | 1 |
| Olomorasib | 1 | 1 | 1 |
| Aflutinib | 1 | 1 | 1 |
| Osimertinib | 1 | 0 | 1 |
| Daraxonrasib | 1 | 0 | 1 |
| AMG 757 | 1 | 0 | 1 |
| Repotrectinib | 1 | 0 | 1 |
| Budesonide | 1 | 0 | 1 |
| Cemiplimab | 1 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Immune checkpoint inhibitors 2 open · Antimetabolites 3
Coming up
8studies finish main data collection within a year2 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 8, phase 3 first
- Dec 2026Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) · Phase 3 · Qilu Pharmaceutical Co., Ltd.
- Nov 2027A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer · Phase 3 · Eli Lilly and Company
- Dec 2026Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients · Instituto Nacional de Cancerologia de Mexico
- Mar 2027Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors · Revolution Medicines, Inc.
- May 2027Understanding New Cachexia Subtypes Through Observational Epidemiological Research · Kaiser Permanente
- Jun 2027TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · Rutgers, The State University of New Jersey
- Aug 2027Real World Registry for Use of the Ion Endoluminal System · Intuitive Surgical
- Nov 2027Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study · AstraZeneca
Who these studies take
Of the 14 Respiratory Tract Neoplasms studies recruiting now, 10 (71%) set no upper age limit and 3 (21%) stop at 75 or younger. 1 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (14%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 12 (86%) | 12 (86%) |
| 30 | 12 (86%) | 12 (86%) |
| 40 | 13 (93%) | 13 (93%) |
| 50 | 14 (100%) | 14 (100%) |
| 65 | 14 (100%) | 14 (100%) |
| 75 | 13 (93%) | 13 (93%) |
| 85 | 10 (71%) | 10 (71%) |
Across all 60 studies, recruiting or not: 12% stop at 75 or younger and 2% at 65; 5% take children; 0% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 60. Browse all 60 → or search them.
- Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)Not yet recruitingNCT07756840Phase 21 country
- A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerRecruitingNCT06119581Phase 329 countries
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsRecruitingNCT07185997Phase 317 countries
- Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyRecruitingNCT02984761Not applicable1 country
- Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.RecruitingNCT07279935Phase 41 country
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/27 countries
- Understanding New Cachexia Subtypes Through Observational Epidemiological ResearchRecruitingNCT077763531 country
- Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC PatientsRecruitingNCT07242547Phase 21 country
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/219 countries
- Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)Not yet recruitingNCT07247786Phase 21 country
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable1 country
- Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer PatientsRecruitingNCT03803787Phase 21 country
- TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for HispanicsRecruitingNCT07165691Not applicable1 country
- PALACE: Cemiplimab Trial According to ctDNA LevelsRecruitingNCT06917573Phase 21 country
- Early Intervention Strategies for Lung CancerRecruitingNCT06988943Not applicable1 country
- A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCRecruitingNCT06177925Phase 21 country
- Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Phase 313 countries
- Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) StudyActive, not recruitingNCT064942411 country
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 21 country
- Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLCActive, not recruitingNCT063760841 country
- Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)CompletedNCT04776447Phase 21 country
- A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)Active, not recruitingNCT06606847Phase 21 country
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 113 countries
- New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyActive, not recruitingNCT04564157Phase 31 country
- Real World Registry for Use of the Ion Endoluminal SystemActive, not recruitingNCT060044401 country
- Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses.CompletedNCT01931579Not applicable1 country
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/216 countries
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04222972Phase 322 countries
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/211 countries
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedNCT05054725Phase 210 countries
- Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLCNo longer availableNCT06841874
- Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung CancerCompletedNCT06145750Not applicable1 country
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/213 countries
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsCompletedNCT04774952Phase 11 country
- Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated PatientsTerminatedNCT04512430Phase 21 country
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 110 countries
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 15 countries
- International Lung Screen Trial (ILST)Active, not recruitingNCT02871856Not applicable2 countries
- A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02826161Phase 31 country
- Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCompletedNCT02904954Phase 21 country
- A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsTerminatedNCT04644315Phase 21 country
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/22 countries
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 11 country
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsStatus unknownNCT03634982Phase 11 country
- Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid TumorsCompletedNCT02897778Phase 11 country
- Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsCompletedNCT02909452Phase 11 country
- Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung CancerCompletedNCT01594398Phase 11 country
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT046974463 countries
- CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedNCT01199068Phase 11 country
- Alberta Lung Cancer Screening ProgramStatus unknownNCT02431962Not applicable1 country